NASDAQ · SDGR
Healthcare · Medical - Healthcare Information Services
$27.18
Up+$1.34 (+4.93%)
Updated Nov 5, 2026, 12:07 AM
SID Score
5.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · SDGR
1M range · 20 trading sessions · Daily adjusted prices
Prices through Nov 3, 2026
SDGR closed at $27.18 after 20 trading sessions, down 0.40% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 3, 2026 | $26.47 | $27.94 | $26.42 | $27.18 | 1.21M |
| Nov 2, 2026 | $27.758 | $27.8561 | $25.935 | $26.19 | 1.39M |
| Oct 30, 2026 | $29.00 | $29.44 | $26.41 | $27.14 | 1.95M |
| Oct 29, 2026 | $30.42 | $31.00 | $29.83 | $29.99 | 1.36M |
| Oct 28, 2026 | $27.07 | $31.07 | $26.80 | $30.87 | 3.32M |
| Oct 27, 2026 | $24.87 | $27.28 | $24.50 | $26.72 | 1.52M |
| Oct 26, 2026 | $23.89 | $24.89 | $23.26 | $24.50 | 1.26M |
| Oct 23, 2026 | $22.56 | $23.96 | $22.01 | $23.80 | 1.16M |
| Oct 22, 2026 | $23.57 | $24.00 | $22.03 | $22.60 | 1.63M |
| Oct 21, 2026 | $23.55 | $24.26 | $23.24 | $23.90 | 1.06M |
| Oct 20, 2026 | $22.77 | $23.70 | $21.73 | $23.40 | 1.38M |
| Oct 19, 2026 | $22.85 | $23.53 | $22.57 | $23.12 | 1.43M |
| Oct 16, 2026 | $25.69 | $26.00 | $22.57 | $22.60 | 2.72M |
| Oct 15, 2026 | $24.50 | $26.14 | $24.01 | $25.48 | 2.37M |
| Oct 14, 2026 | $25.36 | $25.80 | $24.96 | $25.05 | 1.29M |
| Oct 13, 2026 | $25.71 | $26.232 | $25.495 | $25.89 | 1.3M |
| Oct 12, 2026 | $27.10 | $27.51 | $25.41 | $25.91 | 2.15M |
| Oct 9, 2026 | $26.61 | $28.1624 | $26.37 | $27.28 | 2.08M |
| Oct 8, 2026 | $26.79 | $27.05 | $25.69 | $26.39 | 3.08M |
| Oct 7, 2026 | $27.81 | $28.4299 | $26.8701 | $27.29 | 4.56M |
The latest Smart Investors Daily articles mentioning SDGR.
Company
Market Activity
Research & News
SDGR research
Company profile and research snapshot.
Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 20, 2026 | UBS | Neutral | — |
| Oct 16, 2026 | Keybanc | Overweight | — |
| Oct 13, 2026 | TD Cowen | Buy | — |
| Oct 12, 2026 | BMO Capital | Outperform | — |
| May 14, 2026 | Morgan Stanley | Equal-Weight | — |
No generated briefing is available yet.
Yahoo · Nov 3, 2026
SOPHiA GENETICS (SOPH) delivered earnings and revenue surprises of -84.62% and +1.58%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Yahoo · Oct 29, 2026
IRHYTHM HLDGS (IRTC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Yahoo · Oct 29, 2026
Schrödinger’s updated fair value estimate has moved from US$22.29 to US$25.86, which points to a higher price target in the latest round of analyst work. Recent commentary links this shift to growing interest in AI driven drug discovery and to higher sector valuations, while also stressing that expectations around Q3 execution and contracts are already quite high. As you read on, you will see how this evolving narrative around Schrödinger might shape the way you track the stock from...
Yahoo · Oct 28, 2026
Schrodinger (SDGR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning SDGR.
